Uncategorized
Once-monthly aflibercept benefits patients with early persistent fluid
Intravitreal injections of aflibercept every 4 weeks after monthly injections may provide an additional benefit to patients with early persistent fluid from neovascular age-related macular degeneration, a study found.In a post hoc analysis of the VIEW1 and VIEW2 studies, the authors compared Eylea (aflibercept, Regeneron) 2 mg every 4 weeks to aflibercept 2 mg every 8 weeks and Lucentis (ranibizumab, Genentech) 0.5 mg every 4 weeks in eyes that had early persistent fluid.